Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) Non Operating Income (2017 - 2025)

Autolus Therapeutics (AUTL) has disclosed Non Operating Income for 6 consecutive years, with -$7.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non Operating Income rose 50.94% year-over-year to -$7.0 million, compared with a TTM value of $26.2 million through Sep 2025, up 216.65%, and an annual FY2024 reading of $22.3 million, up 9941.44% over the prior year.
  • Non Operating Income was -$7.0 million for Q3 2025 at Autolus Therapeutics, down from $10.9 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $22.1 million in Q4 2024 and bottomed at -$14.2 million in Q3 2024.
  • Average Non Operating Income over 4 years is -$417333.3, with a median of -$503000.0 recorded in 2023.
  • The sharpest move saw Non Operating Income tumbled 1882.74% in 2024, then skyrocketed 1435.31% in 2025.
  • Year by year, Non Operating Income stood at -$5.4 million in 2022, then soared by 192.15% to $5.0 million in 2023, then soared by 342.71% to $22.1 million in 2024, then tumbled by 131.47% to -$7.0 million in 2025.
  • Business Quant data shows Non Operating Income for AUTL at -$7.0 million in Q3 2025, $10.9 million in Q2 2025, and $129000.0 in Q1 2025.